

FROM RESULTS TO ACTIONS: THE IMPLICATIONS FOR HEALTH POLICY MAKING

OVERVIEW

i. General Policy Implications

- a. Levers to influence treatment patterns/
diffusion of technologies?**
- b. Levers to influence health outcomes?**
- c. Challenge to current thinking?**

ii. Implications for UK Policy

- a. Level of intervention rates**
- b. Targeting of interventions**
- c. Cost-effectiveness of treatments**

iii. Implications for research policy

i. GENERAL POLICY IMPLICATIONS



a. WHAT POLICY “LEVERS” AFFECT TREATMENT PATTERNS?

Many suggested:

- **Health spend per capita**
- **Type of health care system**
- **User charges**
- **Doctor numbers**
- **Doctor payment systems**
- **Hospital facilities**
- **Hospital payment systems**
- **Policies on age**

WHAT POLICY “LEVERS” AFFECT TREATMENT PATTERNS? - (contd)

But no easy answers:

- **Relationships (and direction) vary across diseases**
- **Strengths of relationships not clear**
- **Relative importance not clear**
- **Association not causation**
- **“Levers” vary in tractability**

**b. WHAT TREATMENT PATTERNS/
TECHNOLOGIES AFFECT HEALTH
OUTCOMES?**

- **Breast cancer: no clear associations**
- **IHD: no clear associations**
- **Stroke: no clear associations (but some relationship with use of resources)**

WHY LIMITED ASSOCIATION BETWEEN INTERVENTIONS AND HEALTH OUTCOMES?

- **Poor data?**
 - **disease incidence; interventions; outcomes**
- **Interventions ineffective?**
- **Interventions poorly targeted?**
- **Confounding factors?**

IMPLICATIONS



- **More research**
- **Mechanisms to confine diffusion to effective and appropriate interventions**

c. CHALLENGES TO CURRENT THINKING:

- **Where are we out of line?**
- **Why are we out of line?**
- **What can we learn from other countries?**

ii. IMPLICATIONS FOR UK POLICY

1. Value of international dimension in disease based policy making (National Service Frameworks)

2. Review:

- **Why intervention rates low (e.g. revascularisation)**
- **Whether interventions poorly targeted (e.g. breast cancer)**
- **Why resources poorly used (e.g. stroke)**

iii. IMPLICATIONS FOR GOVERNMENT RESEARCH POLICY

1. Support more international comparisons of disease based policies?

2. If yes, should focus be on:

a. Many-country studies or few-country studies (e.g. McKinsey)?

b. Comparisons of whole countries or of hospitals, areas or other sub-units?

c. Standardising data or analysis of existing crude data?

3. What is the right skill mix for such studies?

4. How can the profile of these studies be increased?

